NeuroPace, Inc. (NASDAQ:NPCE), a medical device company specializing in neurological treatments, has been making significant strides in the epilepsy treatment market with its Responsive ...

November 12, 2024NeuroPace, Inc. beats earnings expectations. Reported EPS is $-0.19, expectations were $-0.27. Operator: ...

NeuroPace, Inc. (NASDAQ:NPCE – Get Free Report) has been given a consensus rating of “Moderate Buy” by the six ratings firms that are presently covering the company, Marketbeat Ratings reports.

Consensus $77.1M. Sees FY24 gross margin 72%-74%. The company said, “NeuroPace (NPCE) continues to expect revenue growth to be primarily driven by increasing sales ...

Nov. 04, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced Food and Drug ...

We have also strengthened our leadership team to further capitalize on this momentum and position NeuroPace to take full advantage of the exciting opportunities in front of us,” said Joel Becker, ...

Nov. 12, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reporte The RNS System Post ...

We have also strengthened our leadership team to further capitalize on this momentum and position NeuroPace to take full advantage of the exciting opportunities in front of us,” said Joel Becker ...